Valuation : Axsome Therapeutics, Inc.

Market Cap 10.83B 9.32B 8.76B 8.01B 14.98B 1,022B 15.02B 104B 40.19B 524B 40.65B 39.77B 1,689B P/E 2026 *
-77.3x
P/E 2027 * 44.9x
Enterprise Value 10.67B 9.18B 8.64B 7.89B 14.76B 1,007B 14.8B 102B 39.61B 517B 40.07B 39.19B 1,665B EV / Sales 2026 *
11x
EV / Sales 2027 * 6.65x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-0.80%
1 week+3.85%
Current month+4.11%
1 month-2.90%
3 months-11.04%
6 months+28.01%
Current year+13.16%
1 week 197.05
Extreme 197.0501
210.59
1 month 197.05
Extreme 197.0501
223.4
Current year 152.28
Extreme 152.28
260.19
1 year 112.9
Extreme 112.9
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 11/01/2012
Director of Finance/CFO 51 15/05/2018
Chief Operating Officer 42 31/03/2014
Director TitleAgeSince
Chairman 57 11/01/2012
Director/Board Member 64 30/11/2014
Director/Board Member 58 30/11/2014
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Exercice

Chief Operating Officer

30,000 0.0583%
06/08/26 Exercice

Chief Executive Officer

13,980 0.0272%
01/07/26 Exercice

Chief Executive Officer

148,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%+3.85%+65.12%+162.38% 10.83B
-1.87%+4.22%+44.36%+0.58% 82.65B
-0.57%+1.27%-16.61%-35.57% 60.24B
-2.23%+5.48%+478.96%+33.09% 58.11B
-2.03%-2.62%-8.63%+27.87% 49.68B
-4.58%-2.73%+1.79%+159.87% 46.66B
-1.64%+1.07%+56.98%-17.07% 32.63B
-0.98%+1.91%+46.30%+100.30% 25.69B
-0.19%-4.74%-0.68%+194.68% 22.73B
-1.13%-2.45%+64.66%+108.24% 16.51B
Average -1.60%+0.17%+73.23%+73.44% 40.57B
Weighted average by Cap. -1.83%+0.82%+86.16%+46.00%

Financials

2026 *2027 *
Net sales 966M 831M 782M 715M 1.34B 91.23B 1.34B 9.24B 3.59B 46.81B 3.63B 3.55B 151B 1.56B 1.34B 1.26B 1.16B 2.16B 147B 2.17B 14.94B 5.8B 75.67B 5.87B 5.74B 244B
Net income -140M -121M -114M -104M -194M -13.25B -195M -1.34B -521M -6.8B -527M -515M -21.9B 255M 220M 207M 189M 353M 24.11B 354M 2.44B 948M 12.37B 959M 938M 39.85B
Net Debt -156M -135M -127M -116M -216M -14.77B -217M -1.5B -581M -7.58B -588M -575M -24.42B -435M -375M -352M -322M -602M -41.1B -604M -4.16B -1.62B -21.09B -1.63B -1.6B -67.94B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
04/09/26 US$206.68 -0.80% 438,242
03/09/26 US$208.35 -0.75% 558,821
02/09/26 US$209.92 +3.50% 608,189
01/09/26 US$202.83 +2.17% 656,301
31/08/26 US$198.52 -0.25% 503,716
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
206.68USD
Average target price
285.42USD
Spread / Average Target
+38.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock